New Research Links Glucagon to Early-Stage Type 2 Diabetes

Research into type 2 diabetes has traditionally focused on the role of insulin, specifically how blood glucose levels rise when the body’s cells become less responsive to the hormone produced in the pancreas. However, a study by the German Diabetes Center indicates that the hormone glucagon also plays a significant role in the early stages of the condition.

The findings, published on April 2, 2026, in the journal Diabetes Care, identify a link between increased glucagon levels and the early onset of type 2 diabetes, particularly in individuals with steatotic liver disease, commonly known as fatty liver disease.

The study, titled Increased Early Postprandial Glucagon Concentrations in Humans With Newly Diagnosed Type 2 Diabetes and Steatotic Liver Disease, specifically examined postprandial glucagon concentrations, which are the levels of the hormone measured after eating.

In individuals without type 2 diabetes, insulin and glucagon typically exist in a fine balance to regulate blood glucose. Insulin works to lower blood sugar, while glucagon works to increase it. When this equilibrium is disrupted, it can lead to significant fluctuations in blood glucose levels.

The research suggests that in people newly diagnosed with type 2 diabetes, this balance is compromised by elevated levels of glucagon early after meals.

This elevation is notably associated with steatotic liver disease. The presence of excess fat in the liver may contribute to the dysregulation of glucagon, further complicating the management of glucose levels in the early stages of diabetes.

Glucagon is historically classified as a diabetogenic hormone. Its primary function is to elevate glucose levels in the bloodstream to ensure the body has enough energy during periods of fasting or stress.

According to clinical research published in Diabetol Int., glucagon achieves this increase in glucose through two primary mechanisms:

• Increasing hepatic gluconeogenesis, which is the process by which the liver creates glucose from non-carbohydrate sources.
• Increasing insulin resistance, which hinders the ability of cells to take up glucose from the blood.

Beyond its impact on glucose, glucagon also plays a significant role in the metabolism of amino acids within the liver.

By shifting the focus toward glucagon, the German Diabetes Center’s research highlights a potential second pathway for understanding the progression of type 2 diabetes. While insulin resistance remains a primary driver of the disease, the early rise of glucagon suggests that the hormonal imbalance begins earlier and involves more than just the failure of insulin response.

The connection to steatotic liver disease is particularly relevant, as it suggests that liver health is intrinsically linked to the hormonal regulation of blood sugar. This indicates that the liver’s state may influence how the pancreas secretes glucagon or how the body responds to it after a meal.

Understanding these early hormonal shifts may provide a more comprehensive view of how type 2 diabetes develops, moving beyond a singular focus on insulin deficiency or resistance to a more integrated view of pancreatic hormone interaction.